RxDoctor Payments DataLook up a doctor →

Christopher Bettacchi, MD

Infectious Disease · Marion, VANPI 1083669543

Payments from drug & device makers

$5,814,984in general payments, 2019–2025

Across 1,523 payments — averaging $3818.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.9M
  • Viiv Healthcare Company$2.3M
  • Pfizer$290K
  • AbbVie$181K
  • GSK$143K
  • Insmed, Inc.$4K
  • plus $6K from 25 others
$2,432in research payments, 2019–2025

Across 20 payments — averaging $121.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1K
  • AbbVie$1K

What the payments were for

  • Consulting fees$51,32321%
  • Speaking & faculty fees$140,82458%
  • Travel & lodging$27,80511%
  • Food & beverage$22,9999%
  • Education$2270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,814,984 in reported general payments places this provider in the 95th percentile of 194 infectious disease providers in Virginia.

See all infectious disease providers in Virginia

Medicare billing

Part B allowed, 2024
$1,425,841
Medicare patients
645
Services billed
125,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala119$470,348
TriumeqAbacavir/Dolutegravir/Lamivudi81$296,644
Daptomycin276$217,015
ErtapenemErtapenem Sodium248$125,861
DovatoDolutegravir Sodium/Lamivudine40$121,319
OdefseyEmtricitab/Rilpiviri/Tenof Ala23$89,604
PrezcobixDarunavir/Cobicistat34$80,494
ZerbaxaCeftolozane/Tazobactam14$62,318
TivicayDolutegravir Sodium28$61,365
DescovyEmtricitabine/Tenofov Alafenam14$30,335
Fosfomycin Tromethamine87$23,895
Cefepime Hcl79$13,618
CeftriaxoneCeftriaxone Sodium102$11,821
Nafcillin Sodium14$11,039
MicafunginMicafungin Sodium38$8,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$2,601$500,683133 claims
Viiv Healthcare CompanyTriumeq, Dovato, Tivicay$2,277,700$479,329149 claims
Johnson & JohnsonPrezcobix$430$80,49434 claims
MerckZerbaxa$2,913,412$62,31814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 194 infectious disease providers in Virginia.

Other infectious disease in Marion

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →